Abstract 1709P
Background
Time-to-treatment failure (TTF), in which both disease progression and treatment interruption are regarded as events, is a common measure in clinical trials that can be used as a sensitivity analysis for informative censoring. However, TTF is inappropriate for excessive censoring in the control group as it exaggerates the effect size instead of penalizing the bias. We propose a novel measure, the modified TTF (mTTF), that considers censoring as events only for excessive censoring in the intervention group. Here we examine whether excessive censoring in the intervention could affect the results of randomized controlled trials (RCTs) leading to FDA-approved drugs using mTFF.
Methods
We conducted a cross-sectional study collecting data from phase II and phase III RCTs of FDA drugs approved based on surrogate endpoints between 2010 and 2020. We reconstructed individual patient data from the published Kaplan-Meier curves of the primary surrogate endpoint. The reverse Kaplan-Meier method (i.e., events and censoring are flipped) was used to quantify excess censoring between study groups. The mTTF sensitivity analysis was conducted and statistical significance was calculated using the log-rank test.
Results
One hundred and one RCTs comprising 60,697 patients were included. The most common surrogate endpoint was progression-free survival with 86 (85.1%) of the studies. The median HR for surrogate endpoints was 0.54 (IQR [interquartile range], 0.41 to 0.63) and the median p-value was 3.0*10-5 (IQR, 2.8*10-8 to 1.5*10-3). Following adjustment for excess censoring using the mTTF the median HR was 0.68 (IQR, 0.52 to 0.84) and the median p-value was 4.2*10-3 (IQR, 2.5*10-6 to 0.12). Across all trials, 35 (34.6%) lost statistical significance using the mTTF.
Conclusions
We introduce mTFF as a practical clinical endpoint that is less conservative than the TTF and is sensitive to excessive censoring in the intervention group. Our findings suggest that some studies are associated with an excessive drop-out rate favouring the intervention group that may lead to a false conclusion regarding the efficacy of FDA-approved treatments. Meaningful shared decision-making requires careful consideration of informative censoring.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Markel: Financial Interests, Personal, Financially compensated role: 4c Biomed, Purple Biotech, Biond Biologics, Ella therapeutics, Nucleai, Beyond Air, Stareget; Non-Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme, Sanofi SA, Novartis International AG, Bristol Myers Squib. T. Meirson: Financial Interests, Personal, Full or part-time Employment, I report receiving personal fees from Purple Biotech: Purple Biotech. All other authors have declared no conflicts of interest.
Resources from the same session
1737P - Use of the predictive risk model LungFlagTM for lung cancer screening in screening in a Spanish reference center: A cost-effectiveness analysis
Presenter: Maria Eugenia Olmedo Garcia
Session: Poster session 23
1738P - Impact of digital platforms on exposure to tobacco and new smoking devices: A survey approach
Presenter: Diego de Haro
Session: Poster session 23
1739P - Lung cancer mortality patterns of tobacco users in the United States: A 21-year analysis (1999-2020)
Presenter: Seif Bugazia
Session: Poster session 23
1740P - Geolocation of respiratory tract cancer and its relationship with chronic exposure to PM2.5 pollutants
Presenter: Moisés González-Escamilla
Session: Poster session 23
1741P - Are physicians aware of lung cancer screening benefits and the importance of implementing this? Data from two public hospitals in Buenos Aires province, Argentina
Presenter: Valentin Vidal
Session: Poster session 23
1742P - Gender differences in incidence trends of early-onset GI cancer: The European perspective
Presenter: Irit Ben-Aharon
Session: Poster session 23
1743P - Bridging the gender gap in oncology: GEORGiNA'S quest for equality in academic research
Presenter: Khalid El Bairi
Session: Poster session 23
1744P - Socioeconomic inequalities in the diagnosis and treatment of colon cancer: A population-based English cancer registry study
Presenter: Benjamin Pickwell-Smith
Session: Poster session 23
1745P - Why do adult patients with cancer abandon treatment in India? A nationwide qualitative study to understand the perspectives of healthcare workers
Presenter: Reshma Ayiraveetil
Session: Poster session 23
1746P - Unintended consequences: Working time directives and oncology staff implications
Presenter: Simon Barry
Session: Poster session 23